Here’s What the Street Thinks About ​Schrödinger (SDGR)

​Schrödinger, Inc. (NASDAQ:SDGR) is a scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science. While the stock is trading close to its all-time low, analysts expect more than 69% upside over the next 12-months from the current level. The stock ranks eighth on our of the Best All-Time Low Stocks to Buy in 2026.

​On April 17, Schrödinger, Inc. (NASDAQ:SDGR) maintained a Buy rating by Matt Hewitt from Craig-Hallum. The analyst did not disclose any price targets. The rating comes as the company approaches its fiscal Q1 2026 earnings, scheduled to be released on May 5. The Street expects the company to post roughly $47.63 million in revenue with a GAAP EPS of negative $0.63.

​Earlier, in March, the company presented its strategic goals at the 2026 KeyBanc Capital Markets Healthcare Forum. Management noted that they plan to transition 75% of their software contracts to hosted models in the next 3 years. For 2026, the company plans to achieve 10% to 15% annual contract value growth. Schrödinger, Inc. (NASDAQ:SDGR) is focused on leveraging AI to expand its user base. ​

While we acknowledge the risk and potential of SDGR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SDGR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks to Buy While the Market Is Down and 14 Stocks That Will Double in the Next 5 Years. 

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.